On this page
MBD4
methyl-CpG binding domain 4, DNA glycosylase
MBD4 encodes a specialised DNA repair enzyme that removes damaged methylated cytosine bases, protecting cells from mutations that can lead to cancer. The MBD4 gene provides instructions for making methyl-CpG binding domain protein 4, a DNA glycosylase enzyme that recognises and removes chemically modified bases from DNA.
MBD4 is located on the long (q) arm of chromosome 3, at band 3q21.3. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 3 in the library →Available at Jeen Health
Clinical tests that include this
Overview
MBD4 encodes a dual-function protein that combines DNA damage recognition with enzymatic repair capability [PMID:9630230]. The gene belongs to the base excision repair pathway, a fundamental cellular mechanism for maintaining genetic stability throughout life. Located on chromosome 3, MBD4 produces a 580-amino-acid protein that specifically targets a type of DNA damage arising from the spontaneous chemical breakdown of methylated cytosine bases.
Methylation of cytosine residues occurs naturally throughout the human genome, particularly at CG dinucleotide sequences. These methylated sites are inherently unstable and prone to deamination, a chemical reaction that converts methylated cytosine to thymine, creating a mismatch in the DNA double helix. Without correction, such mismatches become permanent mutations during DNA replication [PMID:10888872]. The MBD4 protein prevents this outcome by detecting and excising the mispaired thymine base, initiating a repair process that restores the correct genetic sequence.
Pathogenic variants in MBD4 follow an autosomal recessive inheritance pattern, meaning that individuals require changes in both gene copies to develop associated health conditions. Loss of MBD4 function increases susceptibility to specific cancer types, particularly colorectal malignancies and haematological cancers [PMID:25263703]. The gene is included in multiple NHS Genomic Medicine Service panels for cancer predisposition, reflecting its clinical significance in hereditary cancer risk assessment.
What the gene does
The MBD4 protein functions as a mismatch-specific DNA glycosylase, initiating base excision repair at sites where methylated cytosine has undergone spontaneous deamination to thymine. This enzymatic activity addresses a fundamental challenge in genome maintenance: methylated CG dinucleotides represent mutation hotspots because the deamination product (thymine) is a normal DNA base rather than an obvious lesion, making detection more complex than for other types of damage.
The protein's methyl-CpG binding domain enables selective recognition of DNA sequences containing methylated cytosine residues. Upon encountering a G:T mismatch at a methylated CG site, MBD4 employs its glycosylase activity to cleave the N-glycosidic bond linking the mismatched thymine to the sugar-phosphate backbone. This catalytic step generates an abasic site, also termed an AP site, where the base has been removed but the DNA backbone remains intact. Subsequent repair enzymes in the base excision repair pathway then process this intermediate: an AP endonuclease cuts the DNA strand, a polymerase fills the single-nucleotide gap with the correct base, and a ligase seals the remaining nick.
Beyond its catalytic function, research suggests that MBD4 participates in transcriptional regulation through its capacity to bind methylated DNA regions. The protein colocalises with heterochromatin and may influence gene expression patterns, although the glycosylase activity remains its primary characterised role. MBD4 shows substrate specificity for thymine or uracil opposite guanine, with the most physiologically relevant substrate being the G:T mismatch arising from methylated cytosine deamination.
The enzyme operates continuously throughout the cell cycle, providing constitutive surveillance of methylated genomic regions. This ongoing activity is particularly important in tissues with high cellular turnover, where the cumulative burden of spontaneous deamination events would otherwise drive progressive mutation accumulation. The protein's function becomes especially critical in maintaining the fidelity of CpG island sequences, which are frequently methylated and concentrated near gene regulatory regions where mutations could have substantial functional consequences.
Video: Genetics 101
Chromosome location
MBD4 resides on the long arm of chromosome 3 at cytogenetic band 3q21.3. This chromosomal region spans approximately 124 million to 131 million base pairs from the chromosome's terminus, placing MBD4 within a gene-dense area of the genome. The gene itself encompasses multiple exons that encode the 580-amino-acid protein, though the precise exon-intron architecture exhibits typical features of genes involved in DNA repair: a modular organisation that separates functional domains into distinct coding segments.
The 3q21.3 locus shows evolutionary conservation across mammals, reflecting the fundamental importance of MBD4 function in vertebrate genome stability. Neighbouring genes in this chromosomal region include other housekeeping genes involved in basic cellular metabolism and regulation, consistent with the constitutive expression pattern observed for MBD4 across diverse tissue types.
Protein structure
The MBD4 protein displays a bipartite domain architecture that integrates DNA recognition and catalytic functions within a single polypeptide chain. The N-terminal region contains a disordered segment spanning amino acids 1 to 36, which lacks stable three-dimensional structure under physiological conditions. Such intrinsically disordered regions often facilitate protein-protein interactions or provide regulatory flexibility, allowing conformational changes in response to binding partners or post-translational modifications.
The methyl-CpG binding domain (MBD) occupies amino acids 76 to 148, forming a compact globular fold that specifically recognises methylated CG dinucleotides embedded within double-stranded DNA. This domain adopts a characteristic wedge-shaped structure that inserts into the major groove of the DNA helix, making base-specific contacts with methylated cytosine residues. The binding mode stabilises the protein at methylated genomic sites, positioning the catalytic machinery for damage detection.
The C-terminal region houses the DNA glycosylase catalytic domain, which contains the active-site residues responsible for cleaving the N-glycosidic bond of mismatched thymine or uracil bases. This domain shares structural homology with other members of the helix-hairpin-helix glycosylase superfamily, featuring a conserved fold that enables base flipping: the enzyme extracts the target base from the DNA helix interior and rotates it into the active site pocket for cleavage. The spatial separation between the MBD domain and the glycosylase domain permits independent function while enabling coordinated action when the protein engages its substrate.
The overall domain organisation positions MBD4 as a scanning molecule: the MBD domain tethers the protein to methylated DNA regions, whilst the glycosylase domain samples adjacent base pairs for mismatches arising from spontaneous deamination. This architecture optimises repair efficiency at the genomic sites most vulnerable to this specific type of damage.
Key variants
Pathogenic variants in MBD4 compromise the protein's ability to recognise or repair deamination damage at methylated cytosine sites, leading to progressive mutation accumulation in affected cells. The variant spectrum includes missense changes that disrupt the MBD domain's DNA-binding capacity, nonsense mutations that truncate the protein before the catalytic domain, and frameshift variants that abolish functional protein production. Each category of variant impairs the base excision repair pathway through distinct molecular mechanisms, but all share the consequence of reduced genomic stability.
Variants affecting the glycosylase active site eliminate catalytic activity whilst potentially preserving DNA-binding function, creating a non-functional protein that may compete with any residual wild-type enzyme. Changes within the MBD domain prevent the protein from localising to methylated genomic regions, effectively rendering the catalytic machinery unable to access its physiological substrates. Regulatory variants that reduce MBD4 expression levels have also been described, decreasing the cellular capacity for methylation-damage repair without completely abolishing enzyme function.
The clinical penetrance of MBD4 variants appears influenced by genetic background and environmental factors. Individuals carrying biallelic pathogenic variants show elevated cancer risk, but the age of onset and specific tumour types vary between families. This heterogeneity likely reflects the stochastic nature of mutation accumulation: the loss of MBD4 function increases mutation rate, but the specific genes that sustain driver mutations determining tumour development differ between individuals.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.1002_1005del | p.Lys335fs | Pathogenic | ★★☆☆ | not provided |
c.1173dup | p.Asp392fs | Pathogenic | ★★☆☆ | Inborn genetic diseases |
c.1198C>T | p.Arg400Ter | Pathogenic | ★★☆☆ | not provided |
c.1208_1211del | p.Ile403fs | Pathogenic | ★★☆☆ | Inborn genetic diseases |
c.1209_1210insAG | p.Glu404fs | Pathogenic | ★★☆☆ | Inborn genetic diseases |
c.1213_1216del | p.Arg405fs | Pathogenic | ★★☆☆ | not provided |
c.1237dup | p.Ser413fs | Pathogenic | ★★☆☆ | Tumor predisposition syndrome 2 |
c.1254del | p.Glu419fs | Pathogenic | ★★☆☆ | Inborn genetic diseases |
c.1273C>T | p.Arg425Ter | Pathogenic | ★★☆☆ | not provided |
c.1394-1_1394insA | - | Pathogenic/Likely pathogenic | ★★☆☆ | not provided |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Biallelic pathogenic variants in MBD4 confer increased susceptibility to several cancer types, predominantly affecting the gastrointestinal tract and haematopoietic system. Colorectal cancer represents the most frequently observed malignancy, with affected individuals often developing tumours at younger ages than the general population. The molecular basis for this cancer predisposition reflects the high proliferation rate of intestinal epithelial cells combined with chronic exposure to mutagens from dietary and microbial sources, creating a context where impaired DNA repair has particularly severe consequences.
Haematological malignancies, particularly acute myeloid leukaemia, constitute the second major disease category associated with MBD4 deficiency. The haematopoietic stem cell compartment undergoes continuous renewal throughout life, with each division cycle presenting opportunities for mutation fixation if DNA repair is compromised. Evidence suggests that MBD4 loss creates a hypermutator phenotype in blood cell precursors, increasing the probability of acquiring oncogenic mutations in genes controlling cell proliferation and differentiation.
The autosomal recessive inheritance pattern means that most individuals with one pathogenic MBD4 variant (carriers) do not show substantially increased cancer risk, as the remaining functional gene copy provides sufficient repair capacity under normal circumstances. Clinical manifestations typically emerge only when both copies carry damaging variants, eliminating MBD4 activity completely.
No disease links recorded for this gene in our reference set.
Inheritance pattern
Conditions caused by pathogenic MBD4 variants typically follow autosomal recessive inheritance.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
UK clinical status
MBD4 appears on multiple NHS Genomic Medicine Service gene panels, reflecting its established role in hereditary cancer predisposition. The gene holds green classification status on the GI Tract Tumours panel and the Haematological Malignancies Cancer Susceptibility panel, indicating strong evidence supporting its clinical validity for these indications. Green status signifies that the gene-disease relationship meets rigorous criteria for use in diagnostic testing within the NHS.
The gene is also included as green-rated in the Inherited Polyposis and Early Onset Colorectal Cancer panel (R211), where it contributes to risk assessment for individuals with personal or family histories of colorectal neoplasia developing before typical screening ages. Additionally, MBD4 appears on the Inherited Predisposition to Acute Myeloid Leukaemia panel (R347), supporting genetic evaluation in families with multiple cases of AML or unusually early disease onset.
Inclusion on these national panels facilitates access to germline genetic testing through NHS pathways for appropriate patients. Testing may be considered when an individual's personal or family history suggests hereditary cancer susceptibility, particularly if colorectal or haematological malignancies occur at young ages or cluster within the family pedigree.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Diet & lifestyle considerations
Whilst MBD4 status itself does not dictate specific lifestyle modifications, individuals with biallelic pathogenic variants may benefit from general cancer-prevention strategies supported by population-level research. Dietary approaches that reduce colorectal cancer risk in the general population might offer particular value for those with impaired DNA repair capacity, though no controlled trials have specifically examined MBD4 variant carriers.
Research in broader populations suggests that diets rich in fibre from whole grains, fruits, and vegetables may support colorectal health through multiple mechanisms, including shorter intestinal transit times and production of beneficial short-chain fatty acids by gut microbiota. Limiting consumption of processed meats and red meat has been associated with reduced colorectal cancer incidence in observational studies. For individuals with MBD4-related cancer predisposition, such dietary patterns might theoretically reduce the mutagen exposure that their compromised repair systems must address, though this remains an area requiring direct investigation.
Maintaining a healthy body weight and engaging in regular physical activity represent evidence-based recommendations for cancer risk reduction across multiple tumour types. Some research indicates that obesity and sedentary behaviour increase colorectal cancer risk through inflammatory and metabolic pathways, effects that could compound the genetic susceptibility conferred by MBD4 deficiency.
Alcohol consumption shows established links to colorectal cancer risk in population studies, with higher intake correlating with increased incidence. The mechanism may involve acetaldehyde-mediated DNA damage and folate metabolism interference. Individuals with inherited DNA repair deficiencies might face amplified risk from alcohol exposure, suggesting that moderation or avoidance could be prudent, though personalised evidence remains limited.
Supplement considerations
No supplements have been proven to compensate for MBD4 deficiency or substantially reduce cancer risk in individuals with biallelic pathogenic variants. The specific nature of MBD4 function - enzymatic removal of damaged DNA bases - cannot be replicated or enhanced through nutritional supplementation, as the process depends on the protein's structural and catalytic properties rather than cofactor availability.
Folate (vitamin B9) has received attention in cancer research because of its role in nucleotide synthesis and DNA methylation metabolism. Some observational studies have suggested that adequate folate status might reduce colorectal cancer risk in general populations, potentially through effects on DNA repair and methylation patterns. However, other research has raised concerns that high-dose folic acid supplementation could promote progression of existing pre-cancerous lesions. For individuals with MBD4-related cancer predisposition, there is no evidence that folate supplementation provides protective benefit, and supplementation should not be undertaken without medical guidance.
Antioxidant vitamins including vitamin C, vitamin E, and selenium have been investigated for cancer-prevention properties because they neutralise reactive oxygen species that can damage DNA. Large randomised trials in general populations have generally failed to demonstrate that antioxidant supplementation reduces cancer incidence, and some studies have shown potential harm. There is no specific evidence supporting antioxidant use in individuals with MBD4 variants, and such supplementation is not recommended as a cancer-prevention strategy without professional oversight.
Anyone considering vitamin or mineral supplementation should discuss the decision with their healthcare provider, particularly in the context of genetic cancer predisposition, where clinical surveillance and medical management take precedence over unproven nutritional interventions.
Frequently asked questions
What does the MBD4 gene do?
MBD4 encodes a DNA repair enzyme that removes damaged thymine bases arising from spontaneous deamination of methylated cytosine residues. This glycosylase function prevents mutations at methylated CG dinucleotide sequences, which are natural hotspots for genetic change if left unrepaired.
How is MBD4-related cancer risk inherited?
MBD4-associated cancer predisposition follows autosomal recessive inheritance, meaning individuals require pathogenic variants in both gene copies to have substantially increased risk. People with one variant (carriers) typically maintain normal DNA repair capacity through their remaining functional copy.
What cancers are associated with MBD4 variants?
Biallelic MBD4 pathogenic variants primarily increase susceptibility to colorectal cancer and acute myeloid leukaemia. These malignancies reflect the gene's role in maintaining genomic stability in tissues with high cellular turnover and continuous proliferation throughout life.
Can MBD4 variants be detected through NHS testing?
Yes, MBD4 appears on multiple NHS Genomic Medicine Service panels with green classification status, including panels for gastrointestinal tumours, haematological malignancies, inherited colorectal cancer, and acute myeloid leukaemia predisposition. Testing availability depends on clinical indication and referral criteria.
Is there a treatment for MBD4 deficiency?
There is no specific treatment to restore MBD4 function itself. Clinical management focuses on cancer surveillance appropriate to the individual's risk profile, which may include more frequent colonoscopy screening or haematological monitoring. Specific protocols should be discussed with a genetics specialist or oncologist.
What is the difference between MBD4 and other DNA repair genes?
MBD4 specifically targets damage at methylated cytosine sites through base excision repair, whereas other DNA repair genes address different lesion types or employ distinct repair mechanisms. For example, mismatch repair genes correct base-pairing errors genome-wide, whilst MBD4 focuses on a particular chemical modification product at methylated sequences.